SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-423771"
 

Search: id:"swepub:oai:DiVA.org:uu-423771" > Cost effectiveness ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden

Andersson, Maria (author)
AstraZeneca Nordic Baltic, Södertälje, Sweden.
Janson, Christer (author)
Uppsala universitet,Lung- allergi- och sömnforskning
Kristensen, Thomas (author)
AstraZeneca Nordic Baltic, Södertälje, Sweden.
show more...
Szende, Agota (author)
Covance, Leeds, W Yorkshire, England.
Golam, Sarowar (author)
AstraZeneca, BioPharmaceut R&D, Global Market Access & Pricing, Gothenburg, Sweden.
show less...
AstraZeneca Nordic Baltic, Södertälje, Sweden Lung- allergi- och sömnforskning (creator_code:org_t)
2020-05-13
2020
English.
In: Journal of Medical Economics. - : TAYLOR & FRANCIS LTD. - 1369-6998 .- 1941-837X. ; 23:8, s. 877-884
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Aim: We investigated cost effectiveness of benralizumab vs. standard of care (SOC) plus oral corticosteroids (OCS) for patients with severe, eosinophilic OCS-dependent asthma in Sweden. Materials and methods: A three-state, cohort-based Markov model of data from three Phase III benralizumab clinical trials (ZONDA [NCT02075255], SIROCCO [NCT01928771], and CALIMA [NCT01914757]) was used to assess the incremental cost-effectiveness ratio of benralizumab vs. SOC plus OCS. Health outcomes were estimated in terms of quality-adjusted life-years (QALYs). The model included costs and disutilities associated with extrapolated OCS-related adverse events. Patients with severe asthma were defined as those receiving OCS >= 5 mg/day. Results: Benralizumab demonstrated a cost-effectiveness ratio vs. SOC plus OCS of 2018 Swedish Kronor (SEK) 366,855 (euro34,127) per QALY gained, based on increases of 1.33 QALYs and SEK 488,742 (euro45,344) per patient. Benralizumab treatment costs contributed most to incremental costs. The probability of benralizumab's being cost-effective with willingness-to-pay (WTP) thresholds between SEK 429,972 (euro40,000) and SEK 752,452 (euro70,000) ranged from 75% to 99%. Limitations: Potential limitations of these analyses include the use of combined data from three different clinical trials, a one-way sensitivity analysis that did not include mortality and transition estimates, and Observational & Pragmatic Research Institute (OPRI) data from the UK as a proxy of the Swedish health care system. Conclusions: The results of these analyses demonstrate that benralizumab has a high probability of being cost-effective compared with SOC plus OCS for a subgroup of patients with severe, eosinophilic asthma receiving regular OCS treatment and may support clinicians, payers and patients in making treatment decisions.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)

Keyword

Benralizumab
cost-effectiveness analysis
oral corticosteroids
severe asthma

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Andersson, Maria
Janson, Christer
Kristensen, Thom ...
Szende, Agota
Golam, Sarowar
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Health Sciences
and Health Care Serv ...
Articles in the publication
Journal of Medic ...
By the university
Uppsala University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view